Home > Protocol Summaries: Compounds > fluticasone furoate

Protocol Summaries: fluticasone furoate

Protocol Summaries for fluticasone furoate
GSK
Study ID		 Phase Title Status
102934 Phase 1 An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects Recruiting
102936 phase 1 A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Recruiting
106837 Phase 3 A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Recruiting
112018 phase 1 Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects. Completed
112059 Phase 3 A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents. Recruiting
112185 phase 4 A phase-IV, open-label study to evaluate safety/tolerability of once-daily AVAMYS (TM) aqueous nasal spray 110mcg among Vietnamese adult patients with established perennial allergic rhinitis (PAR) Completed
112202 Phase 2 A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma Completed
113203 Phase 2 A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray 110 mcg in the treatment in the treatment of uncomplicated acute rhinosinusitis in adults and adolescents >= 12 years of age Active, not recruiting
113342 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent subjects with Allergic Rhinitis Completed
113477 Phase 1 An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects Completed
114812 phase 4 A comparison of patients on AVAMYS™ versus NASONEX™ (Schering Corporation) and FLIXONASE™ on Key Health Outcome Measures Completed
FFA10013 Phase 1 A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects. Completed
FFA106783 Phase 2 See Detailed Description Completed
FFA109684 Phase 2 See Detailed Description Completed
FFA109685 Phase 2 See Detailed Description Completed
FFA109687 phase 2 See Detailed Description Completed
FFR100010 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR) Completed
FFR100012 Phase 3 A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR). Completed
FFR100652 Phase 3 Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis -A Placebo-controlled Study to Determine the Non-inferiority of GW685698 over Fluticasone Propionate Using a Double-blind Manner- Completed
FFR100688 Phase 3 Study of Perennial Allergic Rhinitis -Long term treatment study- Completed
FFR101747 Phase 3 A Randomized, Double-blind, Placebo-controlled, 2-Week Crossover, Knemometric Assessment of the Effect of Once Daily GW685698X Aqueous Nasal Spray 100 mcg on Short Term Growth in Children Ages 6 - 11 Years with Seasonal and/or Perennial Allergic Rhinitis Completed
FFR101782 Phase 4 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis Active, not recruiting
FFR101816 Phase 3 See Detailed Description Completed
FFR103184 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe Completed
FFR104503 Phase 3 See Detailed Description Completed
FFR104861 Phase 3 See Detailed Description Completed
FFR105693 Phase 3 A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study Completed
FFR106080 Phase 3 See Detailed Description Completed
FFR110537 Phase 4 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis Active, not recruiting
FFR111158 Phase 2 A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis Completed
FFR20002 Phase 3 See Detailed Description Completed
FFR30002 Phase 3 See Detailed Description Completed
FFR30003 phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis Completed
FFR30006 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis Completed
FFR30007 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis Completed
FFR30008 Phase 3 See Detailed Description Completed
FFU105924 Phase 4 R, DB, PC, AC, One-Week, Cross-Over, MC Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg FFNS and 200mcg FPNS in Adult Subjects with SAR Completed
FFU105927 Phase 4 R, DB, PC, AC, One-Week, Cross-Over, MCStudy to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcgFluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhiniti Completed
FFU108556 Phase 3 A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject with Allergic Rhinitis Completed
FFU109045 Phase 4 A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed
FFU109047 Phase 4 A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis Completed
FFU111439 Phase 4 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR) Completed
HZA102928 Phase 1 A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects Completed
HZA102940 Phase 1 A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects Completed
HZA105871 Phase 1 A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects Completed
HZA108799 Phase 1 A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800?g) with and without magnesium stearate, in mild/moderate asthmatic patients. Completed

Filter list by: